SpotitEarly has formed a strategic partnership with Fox Chase Cancer Center, including the Institute for Cancer Research and the American Oncologic Hospital, to validate and expand its early cancer detection technology. The collaboration, which will involve clinical trials, supports SpotitEarly’s ongoing expansion in the US as it prepares for commercialization of its breath-based cancer detection test.

Under the master research collaboration agreement, Fox Chase will lead a multi-year, investigator-initiated clinical trial assessing SpotitEarly’s exhaled-breath test in patients undergoing standard-of-care evaluation for suspected lung cancer. The agreement combines direct research funding with a strategic partnership model aimed at accelerating clinical translation. The framework could be applied to additional cancer types and future applications beyond the initial lung cancer program.

Sangeeta Bardhan Cook, chief innovation officer at Fox Chase Cancer Center, said: “SpotitEarly brings an unconventional yet scientifically promising approach to early detection, and we see tremendous potential in their innovative product and technology when combined with our robust clinical expertise. Together, we will open new doors to earlier diagnoses and, ultimately, better outcomes for patients.”

The collaboration builds on SpotitEarly’s prior partnership with Hackensack Meridian Health, announced in July, and reflects the startup’s rapid US expansion since entering the market. Shlomi Madar, CEO of SpotitEarly, said the Fox Chase collaboration was a natural step in scaling the company’s clinical research. He added: “As a leader in cancer research, their team will provide us with access to a vast network of physicians and resources to collaborate on groundbreaking clinical trials and treatments, moving forward our mission of increasing accessibility to early cancer detection technology for millions.”

SpotitEarly’s LUCID bio-AI hybrid platform integrates artificial intelligence and machine learning with trained canine scent detection. Sensors monitor canine behaviour and physiological signals, translating them into standardized and repeatable results for identifying cancer-associated signatures in breath. This non-invasive approach is designed to detect cancer at earlier stages, when treatment options are most effective. In a completed double-blind prospective study with over 1,300 participants, the platform achieved around 94% sensitivity across four common cancers, demonstrating strong performance in early-stage disease.

The Fox Chase collaboration is expected to provide further clinical validation, supporting regulatory readiness and broader adoption of SpotitEarly’s platform. By combining advanced AI and biological detection methods, the company aims to improve early detection, clinical outcomes, and accessibility for patients across the US.